A number of other equities analysts have also recently commented on the company. HC Wainwright reissued a buy rating on shares of Obseva in a report on Monday, May 6th. Zacks Investment Research cut Obseva from a hold rating to a sell rating in a report on Wednesday, March 6th. Wedbush set a $34.00 price target on Obseva and gave the company a buy rating in a report on Friday, January 25th. Finally, TheStreet cut Obseva from a c- rating to a d+ rating in a report on Wednesday, January 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Obseva presently has a consensus rating of Buy and an average price target of $28.57.
Shares of Obseva stock traded down $0.24 during mid-day trading on Wednesday, reaching $12.50. 34,429 shares of the stock traded hands, compared to its average volume of 38,177. Obseva has a fifty-two week low of $10.23 and a fifty-two week high of $20.35. The stock has a market capitalization of $579.38 million, a P/E ratio of -6.54 and a beta of 1.16.
Obseva (NASDAQ:OBSV) last announced its earnings results on Thursday, May 9th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. As a group, equities analysts forecast that Obseva will post -2.11 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in Obseva by 92.1% in the first quarter. Dimensional Fund Advisors LP now owns 135,547 shares of the company’s stock worth $1,734,000 after acquiring an additional 64,974 shares during the period. Wells Fargo & Company MN grew its position in Obseva by 25.3% in the first quarter. Wells Fargo & Company MN now owns 4,953 shares of the company’s stock worth $63,000 after acquiring an additional 1,000 shares during the period. Fosun International Ltd purchased a new position in Obseva in the first quarter worth approximately $2,494,000. JPMorgan Chase & Co. grew its position in Obseva by 159.2% in the first quarter. JPMorgan Chase & Co. now owns 24,482 shares of the company’s stock worth $313,000 after acquiring an additional 15,037 shares during the period. Finally, Wedbush Securities Inc. grew its position in Obseva by 86.1% in the first quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after acquiring an additional 17,950 shares during the period. Institutional investors own 64.62% of the company’s stock.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: Price to Earnings Ratio (PE) Basics
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.